HPLC MS Method for Analysis of Neomycin on Chromni Column

HPLC Method for Analysis of Neomycin on Chromni Column by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Neomycin.

Neomycin is the an aminoglycoside antibiotic with the chemical formula C23H46N6O13. It is primarily used in topical preparations. It is is often combined with other compounds to create widely used medications. Polymyxin B, which combines neomycin, polymyxin B, and hydrocortisone is one of the most prescribed medications in the United States. It works through binding to the 30S subunit of the prokaryotic ribosome, therefore inhibiting prokaryotic translation of mRNA. You can find detailed UV spectra of Neomycin and information about its various lambda maxima by visiting the following link.

Neomycin can be retained and analyzed using the Chromni stationary phase column. The analysis utilizes a gradient method with a simple mobile phase consisting of water and acetonitrile (MeCN). Detection is performed using LC MS.

Condition

ColumnChromni, 3.2 x 100 mm, 3 µm, 100 A, dual ended
Mobile PhaseMeCN/H2O
BufferAmmonium Formate
Flow Rate0.5 ml/min
DetectionLC MS ESI SIM 615(M+H)+
LOD*20 ppm
*LOD was determined for this combination of instrument, method, and analyte, and it can vary from one laboratory to another even when the same general type of analysis is being performed.

Description

Class of CompoundsAntibiotic
Analyzing CompoundsNeomycin

Application Column

Chromni

Column Diameter: 3.2 mm
Column Length: 100 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Neomycin
Application Detection:
LC MS Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.